A Randomized Controlled Trial of Colistin Combined with Sulbactam: 9 g per Day versus 12 g per Day in the Treatment of Extensively Drug-Resistant <i>Acinetobacter baumannii</i> Pneumonia: An Interim Analysis
Extensively drug-resistant <i>A. baumannii</i> (XDRAB) pneumonia has a high mortality rate in hospitalized patients. One of the recommended treatments is colistin combined with sulbactam; however, the optimal dosage of sulbactam is unclear. In an open-label, superiority, randomized contr...
Main Authors: | Chutchawan Ungthammakhun, Vasin Vasikasin, Dhitiwat Changpradub |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-08-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/11/8/1112 |
Similar Items
-
Investigation of the Synergic Effect of the Colistin/ Sulbactam Combination in Carbapenem-Resistant Acinetobacter baumannii complex Strains with Time-Kill and Checkerboard Methods
by: İmdat KILBAŞ, et al.
Published: (2021-03-01) -
Determination of Susceptibility Rates of Nosocomial Acinetobacter baumannii Isolates to Sulbactam by E-test Method
by: Fatih Temoçin, et al.
Published: (2017-03-01) -
<i>Acinetobacter baumannii</i> Resistance to Sulbactam/Durlobactam: A Systematic Review
by: Luigi Principe, et al.
Published: (2022-12-01) -
Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-Resistant <i>Acinetobacter baumannii</i> Infections
by: Petros Rafailidis, et al.
Published: (2024-03-01) -
Alteration of adeS Contributes to Tigecycline Resistance and Collateral Sensitivity to Sulbactam in Acinetobacter baumannii
by: Yunxing Yang, et al.
Published: (2023-06-01)